Chronic spontaneous urticaria (CSU) is a skin condition where hives, deep swelling, or both appear repeatedly for six weeks or longer without any identifiable trigger. Unlike hives caused by a food allergy or physical stimulus like cold or pressure, CSU flares seem to come out of nowhere. The condition affects roughly 0.7% of the general population worldwide and, while not dangerous, can significantly disrupt daily life.
How CSU Differs From Other Types of Hives
Most people have experienced a bout of hives at some point, whether from an allergic reaction, a viral illness, or stress. Those episodes typically resolve within days or a few weeks and are classified as acute urticaria. CSU is different in two important ways: it lasts at least six weeks, and no specific external trigger can be identified.
There is another chronic form called chronic inducible urticaria, where a known physical stimulus causes the flare every time. Someone with cold urticaria, for example, breaks out in hives after exposure to cold temperatures, and the link is reproducible in a clinic with a simple ice-cube test. Similarly, pressure urticaria flares after sustained pressure on the skin, and dermatographic urticaria appears when the skin is firmly stroked or scratched. CSU, by contrast, flares unpredictably. Many people with CSU also have one or more inducible types at the same time, which can make the picture confusing until a doctor sorts it out.
What Happens Inside the Skin
The visible hives and swelling in CSU come from mast cells, a type of immune cell sitting in the skin. When mast cells activate, they release histamine and other inflammatory chemicals that make nearby blood vessels leak fluid into the surrounding tissue. That fluid creates the raised, red, itchy welts characteristic of hives. When the leaking happens in deeper tissue layers, it produces angioedema: puffy, sometimes painful swelling, most often around the eyes, lips, hands, or feet.
The central question in CSU is: what triggers these mast cells when there’s no allergen involved? Research increasingly points to the immune system turning against itself. In roughly half of CSU patients, the body produces autoantibodies, immune proteins that mistakenly target the person’s own mast cells and a related blood cell called a basophil. These autoantibodies attach to receptors on the surface of mast cells and essentially flip the “on” switch, causing the cells to dump their contents without any outside allergen being present. Two main pathways have been identified. In one, the autoantibodies directly latch onto the receptor that normally responds to allergy-related signals. In the other, the body makes antibodies against its own allergy-related proteins, which then cross-link those same receptors and force degranulation. The result is the same: unprovoked bursts of histamine and inflammation.
Who Gets CSU
CSU can develop at any age, though it is more common in adults between their 20s and 50s. Women are affected roughly twice as often as men. The worldwide prevalence of chronic urticaria overall is about 0.7%, and interestingly, studies find a slightly higher rate in children and adolescents than in adults. U.S. claims data show prevalence is highest in children under 11 (about 0.14%) and drops in the 12-to-24 age group before leveling off in middle-aged adults and declining slightly after age 65.
What Daily Life Looks Like
CSU is far more than a cosmetic nuisance. The hives are intensely itchy, can appear anywhere on the body, and often cycle through flares and calm periods with no warning. Individual welts typically fade within 24 hours, but new ones replace them, creating a relentless cycle. Some people wake up clear and are covered in hives by afternoon. Others flare overnight and struggle to sleep.
Sleep disruption is one of the most documented consequences. In one study of 75 CSU patients, nearly 79% had poor sleep quality. The downstream effects of that poor sleep were striking: patients with impaired sleep were 1.6 times more likely to have clinically significant anxiety and nearly 4 times more likely to screen positive for depression compared to CSU patients who slept well. Work and school performance also take a hit. The combination of visible welts, chronic itch, fatigue, and unpredictability creates a quality-of-life burden that research consistently shows is comparable to that of heart disease or other serious chronic conditions.
How CSU Is Diagnosed
There is no single test that confirms CSU. Diagnosis is largely based on your history: hives present most days of the week for six weeks or more, with no consistent trigger you or your doctor can identify. Blood work is typically done not to confirm CSU itself but to rule out other conditions that could be driving the hives. A complete blood count, markers of inflammation like C-reactive protein and sedimentation rate, and sometimes thyroid function tests help screen for infections, inflammatory diseases, or thyroid autoimmunity that can mimic or worsen CSU.
If your doctor suspects an inducible component, provocation testing may be used. This involves applying a specific stimulus (cold, pressure, friction) to a small area of skin and watching for a reaction. If hives only appear with a known trigger, the diagnosis shifts toward chronic inducible urticaria rather than the spontaneous form.
Treatment Approach
Treatment for CSU follows a stepwise approach, starting simple and escalating if needed. The first line is a standard-dose, non-drowsy antihistamine taken daily, not just when hives appear. If that doesn’t bring adequate control after two to four weeks, the dose can be increased up to four times the standard amount. Many people find relief at higher antihistamine doses without significant side effects, though drowsiness can become an issue for some.
For those who don’t respond to escalated antihistamines, the next step is a biologic injection called omalizumab, given once every four weeks. Omalizumab works by binding free-floating allergy antibodies in the blood, reducing the signals that activate mast cells. A large meta-analysis covering over 1,100 patients found that about 72% achieved complete or near-complete hive control after 16 weeks of treatment. Response can be rapid, with some patients noticing improvement within the first week or two, while others take longer. If omalizumab doesn’t work, additional options exist, though they involve stronger immune-suppressing medications with more potential side effects.
How Long CSU Lasts
One of the most common questions people have after diagnosis is whether CSU ever goes away. The answer, for most people, is yes, but the timeline is unpredictable. The average disease duration is estimated at about five years, though severe cases can last longer.
A targeted review of remission studies found that between 21% and 47% of patients go into remission within the first year. By year five, roughly 45% have seen their symptoms resolve. By 20 years, that number climbs to about 73%. These figures mean that while CSU does tend to burn itself out eventually, a significant number of people live with it for many years. Severity at onset, the presence of angioedema, and whether autoantibodies are detected can all influence how long the condition persists, though none of these factors predict the timeline with certainty for any individual.
Remission in CSU doesn’t always mean the condition is gone for good. Some people experience months or years of quiet before a relapse, which can be discouraging. Maintaining a relationship with a specialist who understands the condition helps ensure treatment can be restarted quickly if symptoms return.